Galapagos NV has identified a preclinical compound in its alliance with Janssen Pharmaceutica NV, triggering an $8.7 million milestone payment to Galapagos. Galapagos developed the preclinical candidate against a novel target discovered using its proprietary platform. Galapagos will now begin safety evaluation to advance the compound to Phase I trials. “Four years into the alliance, which started at the novel target stage, we are excited to have delivered the first preclinical candidate,” said ...